Shenzhen Bioeasy Biotechnology Co. Ltd. Total Assets
Shenzhen Bioeasy Biotechnology Co. Ltd. total assets. Based on the latest financial reports, Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) holds total assets worth CN¥1.49 Billion CNY (≈ $217.74 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shenzhen Bioeasy Biotechnology Co. Ltd. market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
Total assets of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See 300942 live share price for real-time trading data and today's change.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Asset Composition Analysis
Shenzhen Bioeasy Biotechnology Co. Ltd. Total Assets Breakdown (December 2025)
Shenzhen Bioeasy Biotechnology Co. Ltd. total assets breakdown as of December 2025. Shenzhen Bioeasy Biotechnology Co. Ltd.'s total assets of CN¥1.49 Billion consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.8% |
| Accounts Receivable | CN¥110.21 Million | 7.2% |
| Inventory | CN¥54.77 Million | 3.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥37.35 Million | 2.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shenzhen Bioeasy Biotechnology Co. Ltd. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Bioeasy Biotechnology Co. Ltd.'s current assets represent 53.6% of total assets in 2025, a decrease from 81.9% in 2016.
- Cash Position: Cash and equivalents constituted 25.8% of total assets in 2025, down from 56.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
Shenzhen Bioeasy Biotechnology Co. Ltd. Competitors by Total Assets
Key competitors of Shenzhen Bioeasy Biotechnology Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Shenzhen Bioeasy Biotechnology Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.29 | 5.47 | 5.72 |
| Quick Ratio | 6.72 | 5.16 | 5.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥688.80 Million | CN¥597.23 Million | CN¥741.46 Million |
Shenzhen Bioeasy Biotechnology Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Shenzhen Bioeasy Biotechnology Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.89 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | CN¥1.52 Billion |
| Market Capitalization | $342.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Bioeasy Biotechnology Co. Ltd.'s assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shenzhen Bioeasy Biotechnology Co. Ltd.'s assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
The table below shows the annual total assets of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.52 Billion ≈ $223.09 Million |
+4.62% |
| 2024-12-31 | CN¥1.46 Billion ≈ $213.23 Million |
+7.43% |
| 2023-12-31 | CN¥1.36 Billion ≈ $198.48 Million |
+5.76% |
| 2022-12-31 | CN¥1.28 Billion ≈ $187.66 Million |
+11.27% |
| 2021-12-31 | CN¥1.15 Billion ≈ $168.65 Million |
+76.53% |
| 2020-12-31 | CN¥652.89 Million ≈ $95.54 Million |
+5.36% |
| 2019-12-31 | CN¥619.67 Million ≈ $90.68 Million |
+108.76% |
| 2018-12-31 | CN¥296.83 Million ≈ $43.44 Million |
+70.79% |
| 2017-12-31 | CN¥173.80 Million ≈ $25.43 Million |
+41.22% |
| 2016-12-31 | CN¥123.07 Million ≈ $18.01 Million |
-- |
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more